- Home
- GAMB vs CVRX Comparison
GAMB vs CVRX Comparison
Compare GAMB & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GAMB | CVRX |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.7M | 171.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GAMB | CVRX |
|---|---|---|
| Price | $4.26 | $5.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $9.79 | ★ $11.40 |
| AVG Volume (30 Days) | ★ 571.2K | 385.4K |
| Earning Date | 03-19-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $154,519,000.00 | $55,969,000.00 |
| Revenue This Year | $32.40 | $11.91 |
| Revenue Next Year | $12.25 | $15.28 |
| P/E Ratio | $92.07 | ★ N/A |
| Revenue Growth | ★ 24.21 | 18.44 |
| 52 Week Low | $4.25 | $4.30 |
| 52 Week High | $17.14 | $15.42 |
Technical Indicators
Market Signals| Indicator | GAMB | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.67 | 34.16 |
| Support Level | $4.25 | $6.27 |
| Resistance Level | $4.74 | $7.03 |
| Average True Range (ATR) | 0.24 | 0.55 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 7.27 | 0.23 |
Price Performance
Historical ComparisonAbout GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.